表紙
市場調查報告書
商品編碼
603913

藥物分析:Durvalumab (Imfinzi)

Imfinzi

出版日期: | 出版商: Datamonitor Healthcare | 英文 57 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供PD-L1為目標的人單株抗體的Durvalumab (Imfinzi) 的相關調查,提供主要國家/地區的銷售額實際成果與預測,就各疾病來看的藥物評估·SWOT分析,及藥物簡介等資訊。

  • 產品簡介
  • Durvalumab (Imfinzi):頭頸癌
  • Durvalumab (Imfinzi):膀胱癌
  • Durvalumab (Imfinzi):非小細胞肺癌 (NSCLC)
目錄
Product Code: DMKC0142963

Drug Overview:

Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells. By inhibiting the PD-1/PD-L1 interaction, Imfinzi reduces the ability of the tumor to evade immune system targeting and enables the activation of T cells and the adaptive immune system

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Imfinzi : Hepatocellular carcinoma (HCC)
    • Imfinzi : Non-small cell lung cancer (NSCLC)
    • Imfinzi : Head and neck cancer
    • Imfinzi : Bladder cancer

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Imfinzi for HCC
  • Figure 1: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for HCC
  • Figure 2: HCC total market value across the US, Japan, and five major EU markets, by country, 2018-27
  • Figure 4: HCC sales in Japan, 2018-27
  • Figure 5: HCC sales in the five major EU markets, by country, 2018-27
  • Figure 6: Datamonitor Healthcare's drug assessment summary for Imfinzi in non-small cell lung cancer
  • Figure 7: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 8: Imfinzi for head and neck cancer - SWOT analysis
  • Figure 6: Price sources and calculations, by country
  • Figure 7: Datamonitor Healthcare's drug assessment summary of Cabometyx for HCC
  • Figure 9: Cabometyx sales for HCC across the US, Japan, and five major EU markets, by country, 2018-27
  • Figure 12: Datamonitor Healthcare's drug assessment summary for Imfinzi in urothelial bladder cancer

LIST OF TABLES

  • Table 1: Imfinzi drug profile
  • Table 2: Trials of Imfinzi for HCC
  • Table 3: Imfinzi for HCC - SWOT analysis
  • Table 4: Imfinzi drug profile
  • Table 5: Imfinzi pivotal trial data in non-small cell lung cancer
  • Table 6: Imfinzi late-phase trial data in non-small cell lung cancer
  • Table 7: Imfinzi ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 8: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 9: Imfinzi patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 10: Imfinzi drug profile
  • Table 11: Imfinzi Phase III trials in head and neck cancer
  • Table 12: Imfinzi early-phase data in head and neck cancer
  • Table 13: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 14: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 15: Imfinzi drug profile
  • Table 16: Imfinzi pivotal trial data in urothelial bladder cancer
  • Table 17: Imfinzi ongoing late-phase trials in urothelial bladder cancer